Patrick Soon-Shiong
Founder & CEO @ NantWorks
Los Angeles, United States
Patrick Soon-Shiong is a Series A investor at NantWorks in Los Angeles focused on Health Care and Biotechnology. Patrick Soon-Shiong is based out of Culver City, California, and is the CEO and Founder of NantOmics. Patrick previously worked at Access to Advanced Health Institute as a Chair of the Board. Patrick Soon-Shiong attended the University of the Witwatersrand. Patrick Soon-Shiong has been received the Distinguished Medical Science Award.
- Total investments:
- 22
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Patrick Soon-Shiong invests in
Stages Patrick Soon-Shiong invests in
Countries Patrick Soon-Shiong invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Series A
- $2M–$26M
- Series B
- $5M–$50M
- Series C
- $20M–$30M
Investment Focus
Industry
- Health Care 7 (32%)
- Biotechnology 4 (18%)
- Software 3 (14%)
- SaaS 2 (9%)
- Energy 2 (9%)
Stage
- Series A 5 (23%)
- Series B 5 (23%)
- Series C 3 (14%)
- Post-IPO Equity 3 (14%)
- Private Equity 2 (9%)
Country
- United States 16 (73%)
- United Kingdom 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Prolific Machines is a biotech company developing cell technologies to redefine how cells are produced for a sustainable and healthy future. It combines cutting-edge technologies to enable cell production at a new scale. The company was founded in 2020 and is based in San Francisco, California. | $50M / Series B / Oct 14, 2026 | ||
| PDS Biotechnology is a biopharmaceutical company. It develops immunotherapies for cancer and other infectious diseases. It develops products to prevent and treat cervical, ovarian, melanoma, leukemia, pancreatic, oral, multiple myeloma, anal, vulvar, and penile cancers. The company offers PDS0101, a treatment for HPV-related cancers; PDS0102, apandemic influenza vaccine; and PDS0103, a line of immunotherapy products for non-viral cancers.PDS Biotechnology Corporation was founded in 2005 and is headquartered in North Brunswick, New Jersey. | $11.3M / Post-IPO Equity / Sep 08, 2026 | ||
| Alyssum Therapeutics is a biotechnology company that focuses on developing next-generation immunotherapies to modulate B cells. | $26M / Series A / Oct 23, 2024 | ||
| Sienza Energy is developing a radical new approach to design and manufacture batteries. The company’s revolutionary strategy is based on a 3D nanotechnology electrode structure that takes advantage of advances in multiple fields over the last decade, providing an approach to battery design that is unique in the industry. By combining these advancesin an innovative way, Sienza can drastically improve the batteries’ energy and power densities — all with the goal of simultaneously reducing the overall battery costs. With this new approach, Sienza Energy can provide even more capability in a range of products, from smart devices to electric vehicles. | Series A / Feb 17, 2022 | ||
| Heliogen is a renewable energy technology company focused on eliminating the need for fossil fuels in heavy industry and powering a sustainable future. The company’s AI-enabled, modular concentrated solar technology aims to cost-effectively deliver near 24/7 carbon-free energy in the form of heat, power, or green hydrogen fuel at scale – forthe first time in history. Heliogen was created at Idealab, the leading technology incubator founded by Bill Gross in 1996. For more information about Heliogen, please visit heliogen.com. | $25M / Series A / Apr 08, 2020 | ||
| NantKwest is a clinical-stage immunotherapy company focused on harnessing the immune system to treat disease. It is a biotechnology company, engages in developing immunotherapeutic agents for various clinical conditions in the United States. The company’s product candidates include activated natural killer candidates for the treatment ofvirally-induced cancers, such as human papilloma virus-induced cervical, and head and neck cancers; ebola; and serious viral, fungal, and bacterial infections, as well as that is in Phase II clinical trials for the treatment of polyoma virus-induced merkel cell carcinoma. | $39M / Post-IPO Equity / Mar 26, 2019 | ||
| Directa Plus is a nanotechnology company, manufactures nanoparticles. | Post-IPO Equity / Jan 30, 2019 | ||
| Heliogen is a renewable energy technology company focused on eliminating the need for fossil fuels in heavy industry and powering a sustainable future. The company’s AI-enabled, modular concentrated solar technology aims to cost-effectively deliver near 24/7 carbon-free energy in the form of heat, power, or green hydrogen fuel at scale – forthe first time in history. Heliogen was created at Idealab, the leading technology incubator founded by Bill Gross in 1996. For more information about Heliogen, please visit heliogen.com. | $10M / Series A / Oct 09, 2018 | ||
| PacketFabric develops a next-generation networking platform to redefine network connectivity. It is a private layer 2 network as a service, providing scalable and secure connectivity between colocation facilities, to major cloud providers, and Internet Exchanges. PacketFabric is cost-effective and scalable network connectivity and all of itsservices are provided via the company's portal and API.PacketFabric was founded on 2015 and is headquartered in Culver City, California. | $25M / Series B / Jan 19, 2018 | ||
| Wibbitz is an automated video creation company that empowers any team to produce professional short form video. The Wibbitz online platform makes it quick and easy to create video for social media, news & entertainment coverage, marketing, communications, recruitment, events and more. Creators have access to customizable video templates,drag-and-drop editing tools, a team of in-house experts, and millions of licensed photos, videos, and soundtracks. The Wibbitz Lightbox API solution enables video creation capabilities within any website or application to engage and retain users with video. Wibbitz powers video for leading brands including Bloomberg, Reuters, Bertelsmann, NBC Universal, HubSpot, and Birchbox. Wibbitz was founded in 2011 and has offices in New York City, Tel Aviv, Paris, and London. | $20M / Series C / Oct 23, 2017 | ||
| See all 22 investments → | |||
Co-Investors
About NantWorks
NantWorks is a convergence of next generation machine vision, object and voice recognition technologies, ultra-low power semiconductors, supercomputing, and advanced networks for the purpose of bringing the digital revolution to healthcare, commerce and digital entertainment to an entirely new level.
NantWorks Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Charles Kenworthy
Executive Vice-President, Corporate Strategy
|
|||
Charles Kim
Executive Vice President and Chief Legal Officer
|
|||
Dora Gruner
Senior Corporate Development Counsel
|
|||
Nancy Valdivia
Director, Strategic Operations/HR; Vice President, Strategic Operations & CHRO
|
|||
Orang Dialameh
CTO
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Patrick Soon-Shiong invest in?
Patrick Soon-Shiong invests primarily in Health Care, Biotechnology and Software startups, most often at Series A and Series B stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Patrick Soon-Shiong invest in?
Patrick Soon-Shiong typically joins rounds of $2M–$26M at Series A, $5M–$50M at Series B and $20M–$30M at Series C. These are whole funding-round sizes, not Patrick Soon-Shiong's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Patrick Soon-Shiong took part in.
How do I contact Patrick Soon-Shiong?
Public channels for Patrick Soon-Shiong include X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Patrick Soon-Shiong last invest?
The most recent investment recorded for Patrick Soon-Shiong closed in Oct 2026. Shizune tracks 22 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
